Research Paper
PLOS GENETICS: Hepatic ribosomal protein S6 (Rps6) insufficiency results in failed bile duct development and loss of hepatocyte viability; a ribosomopathy-like phenotype that is partially p53-dependent (Chen)
April 6, 2023
Sarah A. Comerford, Elizabeth A. Hinnant, Yidong Chen, Robert E. Hammer Sarah A. Comerford, Elizabeth A. Hinnant, Yidong Chen, Robert E. Hammer Abstract Defective ribosome biogenesis (RiBi) underlies a group of clinically diverse human diseases collectively known as ribosomopathies, core manifestations of which include cytopenias and developmental abnormalities that are believed to stem primarily from [...]Neuro-Oncology: Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double strand break repair and augments efficacy of temozolomide in glioblastoma (Chen, Lai, Zheng Labs)
March 23, 2023
Salvador Alejo, Bridgitte E Palacios, Prabhakar Pitta Venkata, Yi He, Wenjing Li, Jessica D Johnson, Chen Yihong, Sridharan Jayamohan, Uday P Pratap, Kyra Clarke, Yi Zou, Yingli Lv, Korri Weldon, Suryavathi Viswanadhapalli, Zhao Lai, Zhenqing Ye, Yidong Chen, Andrea R Gilbert, Takayoshi Suzuki, Rajeshwar R Tekmal, Weixing Zhao, Siyuan Zheng, Ratna K Vadlamudi, Andrew J Brenner, Gangadhara R Sareddy Abstract Background Efficient DNA repair in response to standard chemo and radiation therapies often contributes to GBM therapy resistance. [...]Biopolymers: Biochemical and biophysical characterization of the nucleic acid binding properties of the RNA/DNA binding protein EWS
March 21, 2023
Emily E. Selig, Roohi Bhura, Matthew R. White, Shivani Akula, Renee D. Hoffman, Carmel N. Tovar, Xiaoping Xu, Rachell E. Booth, David S. Libich Abstract EWS is a member of the FET family of RNA/DNA binding proteins that regulate crucial phases of nucleic acid metabolism. EWS comprises an N-terminal low-complexity domain (LCD) and a C-terminal RNA-binding domain (RBD). The RBD is further divided [...]Cell Reports: Nitric Oxide Suppression by Secreted Frizzled-Related Protein 2 Drives Retinoblastoma (Shiio & Houghton Labs)
March 17, 2023
Panneerselvam Jayabal 1, Fuchun Zhou 1, Xiuye Ma 1, Kathryn M. Bondra 1, Barron Blackman 1, Susan T. Weintraub 2 3, Yidong Chen 1 3 4, Patricia Chévez-Barrios 5, Peter J. Houghton 1 3 6, Brenda Gallie 7, Yuzuru Shiio 1 2 3 8 Highlights The autocrine signaling mediated by SFRP2 drives retinoblastoma SFRP2 signaling suppresses NO production and maintains retinoblastoma growth CXADR serves as the receptor for SFRP2 Targeting SFRP2 results in NO production and suppression of retinoblastoma growth Summary Retinoblastoma is a cancer of the infant retina primarily driven by the loss of [...]Cancer Research: Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time (Houghton)
March 15, 2023
Tuyen Duong;Thanh Nguyen; Yan Wang; Tuyen N. Bui; Rossana Lazcano; Davis R. Ingram; Min Yi; Varshini Vakulabharanam; Linjie Luo; Marc A. Pina; Cansu Karakas ; Mi Li; Nicole M. Kettner; Neeta Somaiah; Peter J. Hougton; Osama Mawlawi; Alexander J. Lazar; Kelly K. Hunt; Khandan Keyomarsi Abstract Treatment strategies with a strong scientific rationale based on specific [...]Neuro-Oncology: Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double strand break repair and augments efficacy of temozolomide in glioblastoma (Chen Lab)
March 13, 2023
Salvador Alejo, Bridgitte E Palacios, Prabhakar Pitta Venkata, Yi He, Wenjing Li, Jessica D Johnson, Chen Yihong, Sridharan Jayamohan, Uday P Pratap, Kyra Abstract Background Efficient DNA repair in response to standard chemo and radiation therapies often contributes to GBM therapy resistance. Understanding the mechanisms of therapy resistance and identifying the drugs that enhance the [...]Structure: Order and disorder bound together in SARS-CoV-2 Nsp1 suppress host translation (Libich Lab)
February 6, 2023
David S Libich 1, Antoine Baudin 2 Abstract In this issue of Structure, Wang et al. investigate the interplay between folded and disordered regions of the SARS-CoV-2 non-structural protein 1 (Nsp1) that promotes the suppression of host protein translation. Their investigation will lead to novel avenues to target critical viral functions necessary for host immune-response suppression therapeutically. Read [...]Neuro-Oncology: Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double strand break repair and augments efficacy of temozolomide in glioblastoma (Chen, Lao)
January 23, 2023
Salvador Alejo, Bridgitte E Palacios, Prabhakar Pitta Venkata, Yi He, Wenjing Li, Jessica D Johnson, Chen Yihong, Sridharan Jayamohan, Uday P Pratap, Kyra Clarke, Yi Zou, Yingli Lv, Korri Weldon, Suryavathi Viswanadhapalli, Zhao Lai, Zhenqing Ye, Yidong Chen, Andrea R Gilbert, Takayoshi Suzuki, Rajeshwar R Tekmal, Weixing Zhao, Siyuan Zheng, Ratna K Vadlamudi, Andrew J Brenner, Gangadhara R Sareddy Abstract Efficient DNA repair in response to standard chemo and radiation therapies often contributes to GBM therapy resistance. Understanding the [...]Star Protocols: Protocol to benchmark gene expression signature scoring techniques for single-cell RNA sequencing data in cancer (Zheng Lab)
January 4, 2023
Nighat Noureen123 Xiaojing Wang12 Siyuan Zheng124 • Protocol for benchmarking signature scoring techniques in scRNAseq data analysis • Comparing single-cell and bulk-based approaches in sensitivity and specificity • Using down sampling to simulate the impact of dropouts on signature scoring techniques Summary Scoring gene signatures are common for bulk and single-cell RNA sequencing (scRNAseq) data. [...]Molecular Cancer Theraputics: Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma (Ignatius, Vaseva, Houghton Labs)
January 3, 2023
Nicole R. Hensch, Kathryn Bondra, Long Wang, Prethish Sreenivas, Xiang R. Zhao, Paulomi Modi, Angelina V. Vaseva, Peter J. Houghton, Myron S. Ignatius Abstract In fusion-negative rhabdomyosarcoma (FN-RMS), a pediatric malignancy with skeletal muscle characteristics, >90% of high-risk patients have mutations that activate the RAS/MEK signaling pathway. We recently discovered that SNAI2, in addition to [...]